Beta Bionics (NASDAQ:BBNX – Get Free Report) and OraSure Technologies (NASDAQ:OSUR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Valuation and Earnings
This table compares Beta Bionics and OraSure Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beta Bionics | $100.25 million | 8.51 | -$73.20 million | ($1.65) | -11.49 |
| OraSure Technologies | $115.02 million | 2.37 | -$68.73 million | ($0.69) | -5.74 |
Risk & Volatility
Beta Bionics has a beta of 3.39, meaning that its share price is 239% more volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
Profitability
This table compares Beta Bionics and OraSure Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beta Bionics | -61.31% | -26.30% | -23.25% |
| OraSure Technologies | -43.70% | -19.09% | -16.26% |
Institutional and Insider Ownership
93.5% of OraSure Technologies shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Beta Bionics and OraSure Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beta Bionics | 1 | 4 | 8 | 0 | 2.54 |
| OraSure Technologies | 1 | 1 | 0 | 0 | 1.50 |
Beta Bionics currently has a consensus price target of $22.91, suggesting a potential upside of 20.83%. OraSure Technologies has a consensus price target of $3.00, suggesting a potential downside of 24.24%. Given Beta Bionics’ stronger consensus rating and higher probable upside, research analysts plainly believe Beta Bionics is more favorable than OraSure Technologies.
Summary
OraSure Technologies beats Beta Bionics on 8 of the 14 factors compared between the two stocks.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
About OraSure Technologies
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
